Back to User profile » Dr Keiko Hosohata

Papers published by Dr Keiko Hosohata:


Association of Clopidogrel with Interstitial Lung Disease: Gaining Insight Through the Japanese Pharmacovigilance Database

Kozaru M, Kambara H, Higuchi A, Kagatsume T, Hosohata K

Vascular Health and Risk Management 2024, 20:415-420

Published Date: 2 September 2024

Association Between COVID-19 and Diabetes Management Indices in Japanese Type 2 Diabetes Mellitus Patients: A Single-Center, Retrospective Study

Furumachi K, Kagatsume T, Higuchi A, Kozaru M, Kumagai E, Hosohata K

Infection and Drug Resistance 2024, 17:3759-3767

Published Date: 29 August 2024

Risk Factors for COVID-19 Infection in Adult Patients: A Retrospective Observational Study in Japan

Yoshida A, Furumachi K, Kumagai E, Hosohata K

Infection and Drug Resistance 2024, 17:441-448

Published Date: 3 February 2024

A Pharmacovigilance Study of Drug-Induced Glaucoma Utilizing the Japanese Adverse Event Reporting System

Kozaru M, Iida T, Hosohata K

Clinical Ophthalmology 2023, 17:3645-3653

Published Date: 29 November 2023

Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database

Wakabayashi T, Hosohata K, Oyama S, Inada A, Ueno S, Kambara H, Iida T, Nakatsuji T, Uchida M, Iwanaga K

Therapeutics and Clinical Risk Management 2020, 16:741-747

Published Date: 13 August 2020

Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database

Inada A, Hosohata K, Oyama S, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K

Therapeutics and Clinical Risk Management 2019, 15:59-64

Published Date: 24 December 2018

Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database

Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K

Therapeutics and Clinical Risk Management 2018, 14:1599-1604

Published Date: 5 September 2018